Aptevo Therapeutics Inc.APVONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank9
3Y CAGR-10.4%
5Y CAGR-8.9%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-10.4%/yr
vs -14.7%/yr prior
5Y CAGR
-8.9%/yr
Consistent
Acceleration
+4.3pp
Accelerating
Percentile
P9
Near historical low
vs 5Y Ago
0.6x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
2024$24.25M-16.0%
2023$28.88M-9.1%
2022$31.75M-5.7%
2021$33.69M+141.5%
2020$13.95M-64.0%
2019$38.73M-39.0%
2018$63.52M-0.1%
2017$63.60M-6.7%
2016$68.18M-12.3%
2015$77.77M-